Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 325-333

  Yin, Wen Jin ^a   Lu, Jin Song ^a   Di, Gen Hong ^a   Lin, Yan Ping ^a   Zhou, Li Heng ^a   Liu, Guang Yu ^a   Wu, Jiong ^a   Shen, Kun Wei ^a   Han, Qi Xia ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast neoplasm; Recurrence hazard; Triple negative

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHINA; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 67349217988     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0096-0     Document Type: Article

References (58)

1. A Jemal R Siegel E Ward 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
3. H Joensuu PL Kellokumpu-Lehtinen P Bono 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 10.1056/NEJMoa053028
4. EH Romand EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122
5. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 10.1056/NEJMoa052306
6. Slamon D, Eiermann W, Robert N et al (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Paper presented at the 28th San Antonio Breast Cancer Symposium, Henry B. Gonzalez Convention Center, San Antonio, Texas, USA, 8-11 December 2005
7. S Cleator W Heller RC Coombes 2007 Triple-negative breast cancer: therapeutic options Lancet Oncol 8 235 244 10.1016/S1470-2045(07)70074-8
8. TO Nielsen FD Hsu K Jensen 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 10.1158/1078-0432.CCR-04-0220
9. T Sorlie CM Perou R Tibshirani 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 10.1073/pnas.191367098
10. R Dent M Trudeau KI Pritchard 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR-06-3045
11. KR Bauer M Brown RD Cress 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry Cancer 109 1721 1728 10.1002/cncr.22618
12. SM Rodriguez-Pinilla D Sarrio E Honrado 2006 Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas Clin Cancer Res 12 1533 1539 10.1158/1078-0432.CCR-05-2281
13. LA Carey CM Perou CA Livasy 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 10.1001/jama.295.21.2492
14. S Banerjee JS Reis-Filho S Ashley 2006 Basal-like breast carcinomas: clinical outcome and response to chemotherapy J Clin Pathol 59 729 735 10.1136/jcp. 2005.033043
15. LA Carey EC Dees L Sawyer 2004 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 15 2329 2334
16. BG Haffty Q Yang M Reiss 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 10.1200/JCO.2006.06.5664
17. Chang BW, Decker RH, Haffy BG et al (2007) Incidence of brain metastases in early-stage triple negative breast cancer patients. Paper presented at the 49th American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Los Angeles, California, USA, 28 October-1 November 2007
18. J Kurebayashi T Moriyab T Ishidad 2007 The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races Breast 16 S72 S77 10.1016/j.breast.2007.07.017
19. RJ Simes M Zelen 1985 Exploratory data analysis and the use of the hazard function for interpreting survival data: an investigator's primer J Clin Oncol 3 1418 1431
20. Howell A on behalf of the ATAC Trialists' Group (2005) Author's reply. Lancet 365:1225-1226
21. The Arimidex T Alone or in Combination (ATAC) Trialists' Group 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 10.1016/S1470-2045(07)70385-6
22. I Jatoi A Tsimelzon H Weiss 2005 Hazard rates of recurrence following diagnosis of primary breast cancer Breast Cancer Res Treat 89 173 178 10.1007/s10549-004-1722-0
23. LM McShane DG Altman W Sauerbrei 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8
24. SG Hilsenbeck PM Ravdin CA de Moor 1998 Time-dependence of hazard ratios for prognostic factors in primary breast cancer Breast Cancer Res Treat 52 227 237 10.1023/A:1006133418245
25. PM Grambsch TM Therneau 1994 Proportional hazards tests and diagnostics based on weighted residuals Biometrika 81 515 526 10.1093/biomet/81.3.515
26. PS Hupperets L Volovics LJ Schouten 1997 The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer Am J Clin Oncol 20 546 551 10.1097/00000421-199712000-00002
27. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
28. M Schmitt C Thomssen K Ulm 1997 Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer Br J Cancer 76 306 311
29. R Hahnel K Spilsbury 2004 Oestrogen receptors revisited: long-term follow up of over five thousand breast cancer patients ANZ J Surg 74 957 960 10.1111/j.1445-1433.2004.03215.x
30. Zahl PH, Tretli S (1997) Long-term survival of breast cancer in Norway by age and clinical stage. Stat Med 16:1435-1449. doi :10.1002/(SICI)1097- 0258(19970715)16:13<1435::AID-SIM570>3.0.CO;2-8
31. P-H Zahl 2003 Regression analysis with multiplicative and time-varying additive regression coefficients with examples from breast and colon cancer Stat Med 22 1113 1127 10.1002/sim.971
32. Olopade OI, Ikpatt FO, Dignam JJ et al (2004) "Intrinsic Gene Expression" subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. Paper presented at American Society of Clinical Oncology Annual Meeting, New Orleans, Louisiana, USA, 5-8 June 2004
33. Nishimura R, Arima N (2008) Is triple negative a prognostic factor in breast cancer? Breast Cancer (in press). doi: 10.1007/s12282-008-0042-3
34. Lund MJ, Trivers KF, Porter PL et al (2008) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (in press). doi: 10.1007/s10549-008-9926-3
35. A Goldhirsch JH Glick RD Gelber 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326
36. A Goldhirsch WC Wood RD Gelber 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 10.1093/annonc/mdm271
37. L Harris H Fritsche R Mennel 2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 10.1200/JCO.2007.14.2364
38. DM Abd El-Rehim G Ball SE Pinder 2005 High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 116 340 350 10.1002/ijc.21004
39. C Burgess MS Hunter AJ Ramirez 2001 A qualitative study of delay among women reporting symptoms of breast cancer Br J Gen Pract 51 967 971
40. G Meechan J Collins KJ Petrie 2003 The relationship of symptoms and psychological factors to delay in seeking medical care for breast symptoms Prev Med 36 374 378 10.1016/S0091-7435(02)00053-1
41. CC Burgess AJ Ramirez MA Richards 1998 Who and what influences delayed presentation in breast cancer? Br J Cancer 77 1343 1348
42. MA Richards AM Westcombe SB Love 1999 Influence of delay on survival in patients with breast cancer: a systematic review Lancet 353 1119 1126 10.1016/S0140-6736(99)02143-1
43. NC Facione 1993 Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay Soc Sci Med 36 1521 1534 10.1016/0277-9536(93)90340-A
44. SP Kang M Martel LN Harris 2008 Triple negative breast cancer: current understanding of biology and treatment options Curr Opin Obstet Gynecol 20 40 46
45. JS Ross JA Fletcher GP Linette 2003 The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325 10.1634/theoncologist.8-4-307
46. L Rydén G Landberg O Stål 2008 HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information Breast Cancer Res Treat 109 351 357 10.1007/s10549-007-9660-2
47. J Horiguchi Y Koibuchi K Iijima 2005 Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer Oncol Rep 14 1109 1116
48. M Dowsett C Harper-Wynne I Boeddinghaus 2001 HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer Cancer Res 61 8452 8458
49. CK Osborne V Bardou TA Hopp 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 353 361
50. P Schmid MB Wischnewsky O Sezer 2002 Prediction of response to hormonal treatment in metastatic breast cancer Oncology 63 309 316 10.1159/000066224
51. G Arpino H Weiss AV Lee 2005 Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 1254 1261
52. Y Kun LC How TP Hoon 2003 Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor Hum Mol Genet 12 3245 3258 10.1093/hmg/ddg347
53. CJ Witton JR Reeves JJ Going 2003 Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J Pathol 200 290 297 10.1002/path.1370
54. H Joensuu J Isola M Lundin 2003 Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 923 930
55. TG Karrison DJ Ferguson P Meier 1999 Dormancy of mammary carcinoma after mastectomy J Natl Cancer Inst 91 80 85 10.1093/jnci/91.1.80
56. R Demicheli A Abbattista R Miceli 1996 Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy Breast Cancer Res Treat 41 177 185 10.1007/BF01807163
57. R Demicheli P Valagussa G Bonadonna 2002 Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy Breast Cancer Res Treat 75 127 134 10.1023/A:1019659925311
58. Kilburn LS on behalf of the TNT Trial Management Group (2007) 'Triple Negative' Breast Cancer: a new area for Phase III breast cancer clinical trials. Clin Oncol (R Coll Radio) 20:35-39. doi: 10.1016/j.clon.2007.09.010